Foundation — a swamplink research property

Does R&D spend buy quality?

Half the companies behind these twelve foundations disclose no R&D figure. Among the three that do, spending more does not visibly buy a cleaner or more concentrated formula.

Who discloses R&D at all

Group-wide R&D expense (or, for L'Oréal, its own reported 'Research & Innovation' line) as a percentage of group-wide revenue, in the most recent fiscal year each company discloses it. Company-wide, not product-line-wide: it covers R&D across every category a company sells, not just foundation.

Half the companies behind this corpus disclose no R&D figure whatsoever — not e.l.f. Beauty, not LVMH, not Revlon. Only Coty, Estée Lauder and L'Oréal publish a number a reader can actually cite, and even Estée Lauder's only survives in prose in a footnote, not as a structured financial-statement fact.

Parent company	Products in corpus	R&D / revenue	Fiscal year	Mean SPF	Mean actives above 1% line	Mean allergens	Mean ingredient count
L'Oréal	5	3.10%	2025-12-31	24	1.4	3.8	37
Estée Lauder Companies	4	2.21%	2025-06-30	23.5	4	0	49.5
Coty	1	2.09%	2025-06-30	20	0	6	50
LVMH	1	—	—	20	0	0	36
Revlon	1	—	—	—	0	0	27
e.l.f. Beauty	1	—	—	15	0	0	27

Quality columns are the exact same formulation-derived proxy used throughout this site, averaged per company across its products in this corpus — see price against quality for the full definition.

Does more R&D buy a better formula?

No visible relationship, at n=3. Ranked by R&D as a share of revenue: Coty (2.09%), Estée Lauder (2.21%), L'Oréal (3.10%). Ranked by the formulation-quality proxy, the order scrambles completely — Coty's single product carries the most declared fragrance allergens and zero actives above the 1% line, while Estée Lauder's products average the fewest allergens and the most actives above that line, sitting in the middle of the R&D ranking. Spending more on research is not visibly buying a cleaner or more concentrated formula in this corpus.

Sources for each R&D figure

Coty — SEC Form 10-K (XBRL company facts) — U.S. Securities and Exchange Commission
Estée Lauder Companies — SEC Form 10-K, Note to the financial statements (hand-read, not a discrete XBRL tag) — The Estée Lauder Companies Inc.
L'Oréal — Annual results press release, consolidated profit and loss account — L'Oréal (loreal-finance.com)
LVMH — LVMH does not disclose a group-wide research and development expenditure figure in its annual results release or Universal Registration Document. R&D at LVMH sits inside its Maisons -- Perfumes & Cosmetics is one of five reporting segments -- and is not broken out as its own line or segment note, the same limitation this project already records for LVMH's segment-level gross margin.
Revlon — Revlon filed for Chapter 11 in 2022 and emerged in 2023 as a private company. It no longer files a 10-K, so no current primary R&D figure exists.
e.l.f. Beauty — e.l.f. Beauty's 10-K reports no discrete research and development line, in prose or in XBRL. Product development cost is folded into Selling, general and administrative expenses with no separate disclosure of the amount.

Read this page skeptically. Three companies with a disclosed figure is not a sample size that can establish or rule out a correlation — it is barely enough to plot. R&D-as-percent-of-revenue is company-wide, covering every category each company sells (skincare, fragrance, haircare, and in L'Oréal and LVMH's case, far beyond beauty), not R&D spent on foundation specifically, which no company breaks out. And the quality proxy on this page is exactly what it is everywhere else on this site: formulation read off an FDA filing, never a review score, a dermatologist rating, or a reformulation- frequency count — the axis the original request for this page asked for, and which this project does not use.